Outcomes of Patients After Allo-HSCT With Decitabine and NAC
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The investigators will conduct this prospective and randomized clinical trial, to evaluate
the hematopoietic reconstitution, GVHD and relapse rate of patients after allo-HSCT with
decitabine containing conditional regimen and NAC treatment.
Phase:
Phase 3
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University